Case report on recombinant coagulation factor VIIa in the treatment of three haemophilia A patients with inhibitors in Singapore.
BACKGROUND
We report the first experiences with use of recombinant coagulation Factor VIIa (rFVIIa) in the treatment of haemophilia A patients with inhibitors in Singapore and discuss observations in 3 patients.


METHODS
Case 1 bled on two separate occasions into his neck muscles and vocal cord. Case 2 had gross haematuria from bleeding in the renal calyxes. Case 3 bled into the parotid muscles.


METHODS
rFVIIa in doses, ranging from 50 ug/kg to 90 ug/kg, at different dosing intervals, were used.


RESULTS
Excellent responses were seen in doses of 70 and 90 ug/kg.


CONCLUSIONS
rFVIIa is highly effective, both clinically and cost-wise, in the treatment of these patients.
Ng
H J
HJ
Department of Haematology, Singapore General Hospital, Outram Road, Singapore 169608. ghenhj@sgh.com.sg
Lee
L H
LH
D000328:Adult; D005167:Factor VII / Q000008:administration & dosage / Q000627:therapeutic use*; D015942:Factor VIIa; D006467:Hemophilia A / Q000188:drug therapy*; D006801:Humans; D008297:Male; D011994:Recombinant Proteins / Q000008:administration & dosage / Q000627:therapeutic use*; D012846:Singapore
D011994:Recombinant Proteins; D005167:Factor VII; C103587:recombinant FVIIa; D015942:Factor VIIa